Functional role of respiratory tract haemagglutinin-specific IgA antibodies in protection against influenza-Reference-Cited by-同舟云学术

Functional role of respiratory tract haemagglutinin-specific IgA antibodies in protection against influenza

Published:1990-10 Issue:5 Volume:8 Page:479-485
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Tamura Shin-ichi,Funato Hirono,Hirabayashi Yoshihiro,Kikuta Kiyoshi,Suzuki Yujiro,Nagamine Takashi,Aizawa Chikara,Nakagawa Masaro,Kurata Takeshi

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference21 articles.

1. Immunity to infections on secretory surfaces;Waldman;J. Infect. Dis.,1974

2. Secretory anti-influenza immunity;Shvartsman;Adv. Immunol.,1976

3. Cross-protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T cell reactivity;Liew;Eur. J. Immunol.,1984

4. Dose response of A/Alaska/6/77 (H3N2) cold-adapted reassortant vaccine virus in adult volunteers: Role of local antibody in resistance to infection with vaccine virus;Clements;Infect. Immun.,1983

5. Influenza antibody response following aerosol administration of inactivated virus;Waldman;Am. J. Epidemiol.,1970

Cited by 97 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Detection of SARS-CoV-2-Specific Secretory IgA and Neutralizing Antibodies in the Nasal Secretions of Exposed Seronegative Individuals;Viruses;2024-05-27

2. SARS-CoV-2 infection induces robust mucosal antibody responses in the upper respiratory tract;iScience;2024-03

3. Nasal mucosal IgA levels against SARS-CoV-2 and seasonal coronaviruses are low in children but boosted by reinfection;Journal of Infection;2023-11

4. Subcutaneous immunisation with zymosan generates mucosal IgA-eliciting memory and protects mice from heterologous influenza virus infection;International Immunology;2023-05-04

5. Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial;eBioMedicine;2022-11